MYRIAD GENETICS INC
MYGN evidence brief
What we can confirm
- BioSniper Score:
- 6.9 / 10
- Market Cap:
- $304.2M
- Lead Asset:
- MyChoice CDx (Approved)
What it means
What to watch
Prepared research question
What matters most for MYGN—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · MYGN
Myriad Genetics is a molecular diagnostic company focused on hereditary cancer, prenatal health, and mental health testing, leveraging its commercial reach and recent AI partnerships to drive growth.
Key risk: Continued GAAP net losses
BioSniper Score
Based on 4 of 6 signals
Market Cap
$304.2M
Cash Runway
—
Lead Asset
MyChoice CDx (Approved)
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate for MYRIAD GENETICS INC.
Myriad Genetics is a molecular diagnostic company focused on hereditary cancer, prenatal health, and mental health testing, leveraging its commercial reach and recent AI partnerships to drive growth.
- Total revenue of $190.7M and net loss of -$43.2M for the six months ended June 30, 2026 [sec].
- Cash and equivalents of $116.8M, shareholders' equity of $388.1M, and total debt of $120.7M as of June 30, 2026 [sec].
- Revenue grew at a compound annual growth rate of 11.1% over the past two years, with adjusted EBITDA improving by $61.6 million [sec · filed 2025-04-09].
- Entered a strategic collaboration with PATHOMIQ to add AI technology to its Oncology portfolio, with an exclusive license for prostate cancer [sec · filed 2025-04-09].
- Appointed Samraat Raha as President and CEO effective April 30, 2025 [sec · filed 2026-04-14].
What works
- Established commercial reach in community medicine and a reputation for trusted high-quality tests [sec · filed 2026-04-14].
- Revenue growth of 11% CAGR over two years, with adjusted operating income improving by $54.6 million [sec · filed 2025-04-09].
- Strategic focus on three pillars: Cancer Care Continuum, Prenatal Health and Mental Health, and sustained profitable growth [sec_mda · as of 2026-07-31].
- Recent AI collaboration with PATHOMIQ for prostate cancer testing and integration of Precise Tumor test from Intermountain Precision Genomics [sec · filed 2025-04-09].
What to weigh
- GAAP net loss of -$43.2M for the six months ended June 30, 2026 [sec].
- GAAP operating loss of $(257.4) million in fiscal year 2023, though adjusted operating loss improved [sec · filed 2024-04-17].
- Total debt of $120.7M as of June 30, 2026, representing a significant liability [sec].
- Dependence on successful integration of new technologies and tests (e.g., AI-driven prostate test) to achieve growth targets [sec · filed 2025-04-09].
From the filings
Quoted directly from source documents.
Revenue growth and profitability improvement over two years
“over the past two years, our revenue has increased at a compound annual growth rate of 11.1%, our adjusted operating income has increased by $54.6 million, and our adjusted EBITDA has increased by $61.6 million.”
SEC filings · April 9, 2025
Strategic collaboration with PATHOMIQ for AI in oncology
“We recently entered into a strategic collaboration with PATHOMIQ to add artificial intelligence (AI) technology to our Oncology portfolio including an exclusive license of PATHOMIQ AI technology platform for prostate cancer.”
SEC filings · April 9, 2025
Appointment of new CEO
“Effective April 30, 2025, Samraat Raha was appointed President and Chief Executive Officer”
SEC filings · April 14, 2026
Risks & what to watch (4)›
Key risks
- Continued GAAP net losses — Net loss of -$43.2M for six months ended June 30, 2026, indicating ongoing unprofitability [sec].
- High debt level — Total debt of $120.7M as of June 30, 2026, which may constrain financial flexibility [sec].
- Integration of new technologies — Success of AI-driven prostate test and other new products depends on commercial adoption and integration [sec · filed 2025-04-09].
- Dependence on reimbursement and guidelines — Growth in Prenatal and Mental Health relies on leveraging state biomarker laws and improving reimbursement rates [sec · filed 2026-04-14].
What to watch
- Commercial launch of AI-driven prostate cancer clinical test expected in 2025 [sec · filed 2025-04-09].
- Progress on integrating Precise Tumor test and other acquired assets [sec · filed 2025-04-09].
- Revenue growth trajectory in Prenatal Health and Mental Health segments [sec · filed 2026-04-14].
- Ability to achieve sustained profitability and positive adjusted operating cash flow [sec · filed 2024-01-16].
Sources: SEC filings · SEC MD&A · Generated August 31, 2026 · How we verify sources →
Run MYRIAD GENETICS INC through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available MYRIAD GENETICS INC facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
Cash runway data unavailable
D/E 1.10 · 0% dilution
Lead: Approved
1 candidate
No upcoming catalysts tracked
1 buy · 1 sell (180d)
Pipeline
Financials
Short Interest
as of May 21, 2026- % of float
- 8.6%
- Days to cover
- 7.7
- Shares short
- 7,883,496
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
MYGN short interestGovernance
Frequently asked questions
What is the AI investment thesis for MYRIAD GENETICS INC?
Myriad Genetics is a molecular diagnostic company focused on hereditary cancer, prenatal health, and mental health testing, leveraging its commercial reach and recent AI partnerships to drive growth.
What is MYRIAD GENETICS INC's lead drug candidate?
MYRIAD GENETICS INC's most advanced tracked candidate is MyChoice CDx (Approved) for Determine homologous recombination deficiency (HRD) status in patients with ovarian cancer to provide information on magnitude of benefit for PARP inhibitor therapy.
Who is the CEO of MYRIAD GENETICS INC?
Mr. Samraat S. Raha is the chief executive officer of MYRIAD GENETICS INC (MYGN).
Where is MYRIAD GENETICS INC headquartered?
MYRIAD GENETICS INC (MYGN) is headquartered in Salt Lake City, UT, United States.
What therapeutic areas does MYRIAD GENETICS INC focus on?
MYRIAD GENETICS INC develops therapies across Oncology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.